The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004

John D Mooney; Amanda Weir; Jim McMenamin; Lewis D Ritchie; Tatania V Macfarlane; Colin R Simpson; Syed Ahmed; Chris Robertson; Stuart C Clarke

doi:10.1186/1471-2334-8-53

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004

John D Mooney, Amanda Weir, Jim McMenamin, Lewis D Ritchie, Tatania V Macfarlane, Colin R Simpson, Syed Ahmed, Chris Robertson, Stuart C Clarke

Deanery of Clinical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

For winter 2003/2004 in Scotland, it was recommended that all those aged 65 and over be eligible to receive 23-valent polysaccharide pneumococcal vaccine (23vPPV), which has been shown to be effective in reducing the risk of invasive pneumococcal disease (IPD). We assessed the success of the vaccination programme by examining the age specific incidence rates of IPD compared to four previous winter seasons and estimating vaccination effectiveness.

Original language	English
Pages (from-to)	53
Journal	BMC Infectious Diseases
Volume	8
DOIs	https://doi.org/10.1186/1471-2334-8-53
Publication status	Published - 2008

Access to Document

10.1186/1471-2334-8-53

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004
© 2008 Mooney et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 345 KB

http://www.biomedcentral.com/1471-2334/8/53

Cite this

@article{b55ab743d8364150880f5ce019eed1ee,

title = "The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004",

abstract = "For winter 2003/2004 in Scotland, it was recommended that all those aged 65 and over be eligible to receive 23-valent polysaccharide pneumococcal vaccine (23vPPV), which has been shown to be effective in reducing the risk of invasive pneumococcal disease (IPD). We assessed the success of the vaccination programme by examining the age specific incidence rates of IPD compared to four previous winter seasons and estimating vaccination effectiveness.",

author = "Mooney, {John D} and Amanda Weir and Jim McMenamin and Ritchie, {Lewis D} and Macfarlane, {Tatania V} and Simpson, {Colin R} and Syed Ahmed and Chris Robertson and Clarke, {Stuart C}",

year = "2008",

doi = "10.1186/1471-2334-8-53",

language = "English",

volume = "8",

pages = "53",

journal = "BMC Infectious Diseases",

issn = "1471-2334",

publisher = "BioMed Central",

}

TY - JOUR

T1 - The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004

AU - Mooney, John D

AU - Weir, Amanda

AU - McMenamin, Jim

AU - Ritchie, Lewis D

AU - Macfarlane, Tatania V

AU - Simpson, Colin R

AU - Ahmed, Syed

AU - Robertson, Chris

AU - Clarke, Stuart C

PY - 2008

Y1 - 2008

N2 - For winter 2003/2004 in Scotland, it was recommended that all those aged 65 and over be eligible to receive 23-valent polysaccharide pneumococcal vaccine (23vPPV), which has been shown to be effective in reducing the risk of invasive pneumococcal disease (IPD). We assessed the success of the vaccination programme by examining the age specific incidence rates of IPD compared to four previous winter seasons and estimating vaccination effectiveness.

AB - For winter 2003/2004 in Scotland, it was recommended that all those aged 65 and over be eligible to receive 23-valent polysaccharide pneumococcal vaccine (23vPPV), which has been shown to be effective in reducing the risk of invasive pneumococcal disease (IPD). We assessed the success of the vaccination programme by examining the age specific incidence rates of IPD compared to four previous winter seasons and estimating vaccination effectiveness.

U2 - 10.1186/1471-2334-8-53

DO - 10.1186/1471-2334-8-53

M3 - Article

C2 - 18433473

SN - 1471-2334

VL - 8

SP - 53

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

ER -

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004

Abstract

Access to Document

Fingerprint

Cite this